Telix Pharmaceuticals Limited American Depositary Shares (TLX) Stock Price, News & Analysis

Company Overview

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Key Stats

• Today's Range: $16.12 to $17.19
• 50-Day Range: $13.61 to $20.93
• 52-Week Range: $13.61 to $30.36
• Volume: 28,314 shs
• Average Volume: 27,654 shs
• Market Capitalization: $5.69 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $22.00
• Consensus Rating: Buy

TLX Stock Analysis - Frequently Asked Questions

How have TLX shares performed this year?

Telix Pharmaceuticals Limited American Depositary Shares' stock was trading at $15.40 at the start of the year. Since then, TLX stock has increased by 9.4% and is now trading at $16.84.
View the best growth stocks for 2025 here.

When did Telix Pharmaceuticals Limited American Depositary Shares IPO?

Telix Pharmaceuticals Limited American Depositary Shares (TLX) raised $202 million in an initial public offering (IPO) on Friday, June 14th 2024. The company issued 17,000,000 shares at $11.87 per share.

How do I buy shares of Telix Pharmaceuticals Limited American Depositary Shares?

Shares of TLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 4/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TLX
• Previous Symbol: NASDAQ:TLX
• CIK: 2007191
• Web: www.telixpharma.com
• Phone: 61-3-9093-3855
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $22.00
• High Stock Price Target: $22.00
• Low Stock Price Target: $22.00
• Potential Upside/Downside: +30.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $783.21 million
• Price / Sales: 7.26
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 337,710,000
• Free Float: N/A
• Market Cap: $5.69 billion
• Optionable: N/A
• Beta: N/A